Literature DB >> 24947249

Testosterone serum levels and prostate cancer prognosis: the double face of Janus.

Francesca Valcamonico1, Laura Ferrari, Francesca Consoli, Vito Amoroso, Alfredo Berruti.   

Abstract

Entities:  

Keywords:  castrate-resistant disease; prognosis; prostate cancer; testosterone serum levels

Mesh：

Substances：

Year:  2014        PMID： 24947249     DOI： 10.2217/fon.14.1

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  3 in total

1.  Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients.

Authors:  Francesca Bedussi; Francesca Valcamonico; Alessandra Mosca; Sandra Sigala; Laura Ferrari; Carlo Terrone; Alberto Dalla Volta; Giansilvio Marchioro; Vittorio Ferrari; Oscar Alabiso; Maurizio Memo; Alfredo Berruti
Journal:  Endocrine       Date:  2015-12-21       Impact factor: 3.633

2.  Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.

Authors:  Elahe A Mostaghel; Brett T Marck; Orpheus Kolokythas; Felix Chew; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Phillip W Kantoff; Steven P Balk; Mary-Ellen Taplin; Nima Sharifi; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2021-08-18       Impact factor: 12.531

3.  Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy.

Authors:  Minyong Kang; Sangchul Lee; Jong Jin Oh; Sung Kyu Hong; Sang Eun Lee; Seok-Soo Byun
Journal:  Prostate Int       Date:  2015-10-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.